5-甲酰基噻唑-2-氨基甲酸叔丁酯 | 391668-77-2

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲酰基噻唑-2-氨基甲酸叔丁酯
• 中文别名: (5-甲酰基-2-噻唑)-氨基甲酸叔丁酯；5-醛基噻唑-2-氨基甲酸叔丁酯
• 英文名称: tert-butyl (5-formylthiazol-2-yl)carbamate
• 英文别名: tert-butyl N-(5-formyl-1,3-thiazol-2-yl)carbamate
• CAS: 391668-77-2
• 化学式: C₉H₁₂N₂O₃S
• mdl: MFCD09834789
• 分子量: 228.272
• InChiKey: LKFCHUSAPKBABQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.320±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  96.5
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  5-甲酰基噻唑-2-氨基甲酸叔丁酯 在 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以100%的产率得到tert-butyl {5-[(E)-(hydroxyimino)methyl]-1,3-thiazol-2-yl}carbamate
  参考文献：
  名称：

  Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors

  摘要：

  The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory activity and excellent selectivity against a panel of various serine-threonine and tyrosine kinases, as exemplified by compound 46. We found also that the position and nature of the substituent on the thiazole play key roles in cellular potency. Compounds with an acetanilide substituent at C5' have the greatest cellular activity. The importance of the C5' position for substitution has been rationalized by ab initio molecular orbital calculations. Results show that the planar conformation with the sulfur of the thiazole next to the quinazoline N-3 is strongly favored over the other possible planar conformation. Compound 46 is a potent suppressor of the expression of phospho-histone H3 in tumor cells in vitro as well as in vivo, where 46, administered as its phosphate prodrug 54, suppresses the expression of phospho-histone H3 in subcutaneously implanted tumors in nude mice.

  DOI：

  10.1021/jm050786h
• 作为产物：
  描述：

  2-(叔丁氧酰胺)噻唑-5-甲酸乙酯 在 manganese(IV) oxide 、 二异丁基氢化铝 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 29.0h， 生成 5-甲酰基噻唑-2-氨基甲酸叔丁酯
  参考文献：
  名称：

  TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE

  摘要：

  本发明涉及新型三环螺环衍生物，包括该三环螺环衍生物的药物组合物，以及利用这些化合物治疗或预防过敏、过敏引起的气道反应、充血、心血管疾病、炎症性疾病、消化系统紊乱、神经系统紊乱、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、糖尿病并发症、糖耐量受损或空腹血糖异常。

  公开号：

  US20110166124A1
• 作为试剂：
  描述：

  (5-(羟基甲基)噻唑-2-基)氨基甲酸叔丁酯 、 Cornforth reagent 、 四氢呋喃 在 silica gel 、 二氯甲烷 、 乙酸乙酯 、 desired product 、 5-甲酰基噻唑-2-氨基甲酸叔丁酯 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 以to afford (5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (compound 62.3)的产率得到5-甲酰基噻唑-2-氨基甲酸叔丁酯
  参考文献：
  名称：

  THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS

  摘要：

  本发明提供具有以下式子的化合物：其中R1，R2，X1，X2，L1，L2，Y和Z在本类和子类中定义，并描述了其药物组成物，如本类和子类中一般所述。这些化合物可用作蛋白激酶（例如，极光激酶）的抑制剂，因此可用于治疗极光激酶介导的疾病。

  公开号：

  US20100179123A1

文献信息

• Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
  申请人：Mutahi W. Mwangi

  公开号：US20070167435A1

  公开（公告）日：2007-07-19

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR 5 )—, —C(N—OR 5 )—CH(R 6 )—, —CH(R 6 )—C(N—OR 5 )—, —O—, —OCH 2 —, —CH 2 O— or —S(O) 0-2 —; Y is —O—, —(CH 2 ) 2 —, —C(═O)—, —C(═NOR 7 )— or —SO 0-2 —; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R 1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R 2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combination with other agents.

  揭示了以下化合物的结构式或其药学上可接受的盐或溶剂，其中：M为CH或N；U和W分别为CH，或者U和W中的一个为CH，另一个为N；X为键，烷基，—C(O)—，—C(N—OR5)—，—C(N—OR5)—CH(R6)—，—CH(R6)—C(N—OR5)—，—O—，—OCH2—，—CH2O—或—S(O)0-2—；Y为—O—，—(CH2)2—，—C(═O)—，—C(═NOR7)—或—SO0-2—；Z为键，可选择地取代的烷基或被杂原子或杂环基中断的烷基；R1为可选择地取代的烷基，环烷基，芳基，芳基烷基，杂芳基，杂环烷基或苯并咪唑基或其衍生物；R2为可选择地取代的烷基，烯基，芳基，芳基烷基，杂芳基，杂芳基烷基，环烷基或杂环烷基；其余变量如规范中所定义；使用这些化合物，单独或与其他药剂联合使用，治疗由过敏引起的气道反应、充血、糖尿病、肥胖症、与肥胖有关的疾病、代谢综合征和认知缺陷障碍的组合物和方法。
• Thienopyrimidines useful as Aurora kinase inhibitors
  申请人：Lew Willard

  公开号：US20060035908A1

  公开（公告）日：2006-02-16

  The present invention provides compounds having the formula: wherein R 1 , R 2 , X 1 , X 2 , L 1 , L 2 , Y and Z are as defined in classes and subclasess herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

  本发明提供具有以下公式的化合物： 其中R1、R2、X1、X2、L1、L2、Y和Z的定义如本文中的类和子类中所定义，并且所述的药物组合物，如本文中一般描述和子类中描述的那样，这些化合物可用作蛋白激酶（例如Aurora）的抑制剂，因此可用于治疗由Aurora介导的疾病。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2016046530A1

  公开（公告）日：2016-03-31

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

  本发明涉及新型化合物和制备去泛素化酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C端水解酶L1（UCHL1）。本发明进一步涉及在癌症和其他适应症治疗中使用DUB抑制剂。本发明的化合物包括具有式（I）或其药用可接受盐的化合物，其中R1至R8如本文所定义。
• Medicine comprising dicyanopyridine derivative
  申请人：——

  公开号：US20030232860A1

  公开（公告）日：2003-12-18

  Compounds having a high conductance-type of calcium-activated K channel opening effect and a smooth muscle relaxant effect for bladder based on the K-channel opening effect, which can be used in treating pollakiuria and urinary incontinence, are provided. 3,5-Dicyanopyridine derivatives or their salts.

  基于K通道开放效应的高导电型钙激活K通道开放效应和平滑肌松弛剂效应的化合物，可用于治疗尿频和尿失禁。提供3,5-二氰基吡啶衍生物或其盐。
• ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION
  申请人：Bhuniya Debnath

  公开号：US20100310493A1

  公开（公告）日：2010-12-09

  Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. The disclosure also provides process of preparation of these acetamide derivatives.

  乙酰胺衍生物，它们的立体异构体、互变异构体、前药、药用可接受盐、多型体、溶剂合物及其配方，用于预防、管理、治疗、控制疾病和/或医疗状况的进展，或者作为激活葡萄糖激酶有益时的辅助治疗，已被披露。该披露还提供了这些乙酰胺衍生物的制备方法。